>
Switch to:

OncoCyte Quick Ratio

: 2.53 (As of Jun. 2021)
View and export this data going back to 2015. Start your Free Trial

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. OncoCyte's quick ratio for the quarter that ended in Jun. 2021 was 2.53.

OncoCyte has a quick ratio of 2.53. It generally indicates good short-term financial strength.

The historical rank and industry rank for OncoCyte's Quick Ratio or its related term are showing as below:

NAS:OCX' s Quick Ratio Range Over the Past 10 Years
Min: 0.58   Med: 2.66   Max: 12.82
Current: 2.53

0.58
12.82

During the past 8 years, OncoCyte's highest Quick Ratio was 12.82. The lowest was 0.58. And the median was 2.66.

NAS:OCX's Quick Ratio is ranked lower than
79% of the 316 Companies
in the Biotechnology industry.

( Industry Median: 4.09 vs. NAS:OCX: 2.53 )

OncoCyte Quick Ratio Historical Data

The historical data trend for OncoCyte's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Quick Ratio
Premium Member Only Premium Member Only Premium Member Only 2.97 1.91 1.55 5.17 1.03

OncoCyte Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Quick Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.70 1.35 1.03 6.49 2.53

Competitive Comparison

For the Biotechnology subindustry, OncoCyte's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

OncoCyte Quick Ratio Distribution

For the Biotechnology industry and Healthcare sector, OncoCyte's Quick Ratio distribution charts can be found below:

* The bar in red indicates where OncoCyte's Quick Ratio falls into.



OncoCyte Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

OncoCyte's Quick Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Quick Ratio (A: Dec. 2020 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(9.226-0)/8.996
=1.03

OncoCyte's Quick Ratio for the quarter that ended in Jun. 2021 is calculated as

Quick Ratio (Q: Jun. 2021 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(49.995-0)/19.775
=2.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoCyte  (NAS:OCX) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


OncoCyte Quick Ratio Related Terms

Thank you for viewing the detailed overview of OncoCyte's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte Business Description

OncoCyte logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, the company also developing screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through United States and it earns revenue from the sale of diagnostic tests.
Executives
Carter Jennifer L. director C/O DFP SPONSOR LLC 780 THIRD AVENUE, 37TH FLOOR NEW YORK NY 10017
Kalajian Tony T officer: Sr.VP/Chief Accounting Officer 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Parker Albert P officer: Chief Operating Officer C/O ONCOCYTE CORPORATION 1010 ATLANTIC AVENUE, SUITE 102 ALAMEDA CA 94501
Levine Mitchell S officer: Chief Financial Officer ONE FERRY BUILDING, SUITE 255 SAN FRANCISCO CA 94111
Andrews Ronald Asbury director, officer: Chief Executive Officer 5791 VAN ALLEN WAY CARLSBAD CA 92008
Redmond Cavan M. director 5 GIRALDA FARMS MADISON NJ 07940
Griffith Melinda director 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Arno Andrew director C/O MERRIMAN CURHAN FORD GROUP, INC. 600 CALIFORNIA STREET, 9TH FLOOR SAN FRANCISCO CA 94108
Kingsley Alfred D director 150 E 57TH STREET NEW YORK NY 10022
Last Andrew J. director 3420 CENTRAL EXPRESSWAY SANTA CLARA CA 95051
Broadwood Capital Inc 10 percent owner 724 FIFTH AVENUE 9TH FLOOR NEW YORK NY 10019
Broadwood Partners, L.p. 10 percent owner BROADWOOD CAPITAL INC. 724 FIFTH AVENUE, 9TH FLOOR NEW YORK NY 10019
Bradsher Neal C 10 percent owner PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: BRADSHER NEAL C a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Ross Douglas T. officer: Chief Medical Officer 15 CUSHING IRVINE CA 92618
Sundar Padma officer: SVP, Marketing & Market Access 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501

OncoCyte Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)